Journal: Communications Biology
Article Title: Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes
doi: 10.1038/s42003-022-04254-3
Figure Lengend Snippet: a – h Intravital imaging of CT26 LacZ tumor microenvironment after initial ( a – d ) or second dose ( e – h ) of VSV-AF647. Virus (blue, arrows) delivered as a first dose interacts with tumor cells ( a ), endothelium ( b ), neutrophils ( c ), and other leukocytes ( d ). Virus delivered as a second dose is mainly captured by monocytes defined as CD11b + Ly6G - cells ( e ), expressing Ly6C ( f ), CD169 ( g ), and F4/80 ( h ). Vessels counterstained with FITC-BSA (gray) and delineated by white dashed lines. Scale bar, 25 µm. i Quantification of VSV microdistribution in tumor microenvironment after single or repeated VSV administration. Results are shown as percentage of total VSV-bound cells and plotted as mean ± SEM ( n = 7; two-way ANOVA followed by Sidak’s multiple comparisons test). j FC analysis of intravascular leukocytes in tumor samples at the time of first or second VSV treatment. Intravascular fraction of leukocytes is identified by anti-CD45 injected into the tail vein 10 minutes before tissue collection. Results are shown as percentage of intravascular cells and plotted as mean ± SEM ( n = 4; unpaired t-test). k FC analysis of blood samples collected from untreated mice or 48 h post VSV i.v. injection (10 6 PFU). Results are shown as percentage of CD45 + cells and plotted as mean ± SEM ( n = 4; unpaired t-test). l FC analysis of select leukocyte populations in CT26 LacZ tumor at the time of first or second VSV treatment (see also Supplementary Fig. ). Results are shown as percentage of CD45 + cells and plotted as mean ± SEM (unpaired t -test).
Article Snippet: Rat anti-mouse CD8a eFluor® 660 (53-6.7, 0.2 mg/ml), PE/Cy7-conjugated rat anti-mouse CD11b (M1/70, 0.2 mg/ml) were purchased from eBioscience (San Diego, CA).
Techniques: Imaging, Expressing, Injection